The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Open accessAbstract
Interest in serotonergic involvement in Parkinson's disease (PD) has focussed recently on the possibility that the remaining serotonin neurons innervating striatum (caudate and putamen) might release dopamine as a 'false transmitter'--an action that could have both beneficial and harmful (e.g. promotion of levodopa-induced dyskinesias) consequences. Evidence for a brain serotonergic disturbance in PD is derived in large part from findings of decreased binding of different radioligands to the serotonin transporter (SERT), one 'marker' of serotonin neurons. However, it is not known whether the reported changes in SERT binding reflect actual changes in levels of SERT protein or whether concentrations of all serotonin markers are similarly and markedly decreased in the two striatal subdivisions. We measured levels of SERT immunoreactivity, and for comparison, protein levels of tryptophan hydroxylase (TPH; the marker synthetic enzyme) using a Western blot procedure, as well as concentrations of serotonin, its metabolite 5-hydroxyindoleacetic acid (5-HIAA), and dopamine by HPLC in post-mortem striatum of patients with PD and normal controls. Whereas concentrations of dopamine were severely decreased (caudate, -80%; putamen, -98%) and showed little (caudate) or no (putamen) overlap between individual control and patient values, levels of all four serotonin markers were less markedly reduced (-30% to -66%) with some patients having distinctly normal levels. Unlike the preferential loss of dopamine in putamen, the caudate was affected more than putamen by loss of all serotonin markers: serotonin (-66% versus -51%), 5-HIAA (-42% versus -31%), SERT (-56% versus -30%) and TPH (-59% versus -32%). Striatal serotonin concentration was similar in the subset of patients reported to have had dyskinesias versus those not reported to have had this drug complication. Previous findings of decreased SERT binding are likely explained by loss of SERT protein. Reduced striatal levels of all of the key serotonergic markers (neurotransmitter and metabolite, transporter protein, synthesizing enzyme protein) provide strong evidence for a serotonergic disturbance in PD, but with some patients affected much more than others. The more marked caudate reduction suggests that raphe neurons innervating this area are more susceptible to 'damage' than those innervating putamen and that any functional impairment caused by striatal serotonin loss might primarily involve the caudate. Questions related to the, as yet undetermined, clinical consequences in PD of a striatal serotonin deficiency (caudate: cognitive impairment?) and preservation (putamen: levodopa-induced dyskinesias?) should be addressed in prospective brain imaging and pharmacological studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Self-citationEhringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Self-citationWhat contributes to quality of life in patients with Parkinson's disease?
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., & Agid, Y. (1983) · Brain Research · doi:10.1016/0006-8993(83)90993-9 · Cited by 726
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Bjorklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 636
The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease
Paulus, W., & Jellinger, K. (1991) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199111000-00006 · Cited by 554
de la Fuente-Fernandez, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 402
Cited by
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
Panula, P., Chen, Y.-C., Priyadarshini, M., Kudo, H., Semenova, S., Sundvik, M., & Sallinen, V. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.010 · Cited by 453
The neurobiological basis of cognitive impairment in Parkinson's disease
Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014) · Movement Disorders · doi:10.1002/mds.25857 · Cited by 366
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction
Pavese, N., Metta, V., Bose, S. K., Chaudhuri, K. R., & Brooks, D. J. (2010) · Brain · doi:10.1093/brain/awq268 · Cited by 333
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 306
Maillet, A., Krack, P., Lhommée, E., Météreau, E., Klinger, H., Favre, E., Le Bars, D., Schmitt, E., Bichon, A., Pelissier, P., et al. (2016) · Brain · doi:10.1093/brain/aww162 · Cited by 282
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Rylander, D., Parent, M., O'Sullivan, S. S., Dovero, S., Lees, A. J., Bezard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 262
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145
Serotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00922-9 · Cited by 131
Serotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113
Tong, Q., Zhang, L., Yuan, Y., Jiang, S., Zhang, R., Xu, Q., Ding, J., Li, D., Zhou, X., & Zhang, K. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.016 · Cited by 81
Dong, X.-L., Wang, X., Liu, F., Liu, X., Du, Z.-R., Li, R. W., Xue, C.-H., Wong, K.-H., Wong, W.-T., Zhao, Q., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.180 · Cited by 75
Parkinson's disease: opportunities for novel therapeutics to reduce the problems of levodopa therapy
FOX, S., CHUANG, R., & BROTCHIE, J. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00923-0 · Cited by 39
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease
Janakiraman, U., Manivasagam, T., Justin Thenmozhi, A., Dhanalakshmi, C., Essa, M. M., Song, B.-J., & Guillemin, G. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.01.046 · Cited by 36
Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia
Vegas-Suarez, S., Paredes-Rodriguez, E., Aristieta, A., Lafuente, J. V., Miguelez, C., & Ugedo, L. (2019) · International Review of Neurobiology · doi:10.1016/bs.irn.2019.06.013 · Cited by 26
Cao, X., Du, Z.-R., Liu, X., Wang, X., Li, C., Zhou, S.-N., Liu, J.-R., Xu, P.-Y., Ye, J.-L., Zhao, Q., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115100 · Cited by 15
Metadata
- Authors
- Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L.-J., Guttman, M., & Furukawa, Y.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-22
- Volume
- 131
- Issue
- Pt 1
- Pages
- 120-31
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1992633971
- Cited by
- 375
- References
- 57
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.